Terms: = Skin cancer AND AKT1, P31749, RAC-ALPHA, RAC, PRKBA, PKB-ALPHA, PKB, MGC99656, AKT, ENSG00000142208, 207 AND Clinical Outcome
18 results:
1. A nanotherapeutic strategy that engages cytotoxic and immunosuppressive activities for the treatment of cancer recurrence following organ transplantation.
Yang Z; Xie H; Wan J; Wang Y; Zhang L; Zhou K; Tang H; Zhao W; Wang H; Song P; Zheng S
EBioMedicine; 2023 Jun; 92():104594. PubMed ID: 37167784
[TBL] [Abstract] [Full Text] [Related]
2. MrgprF acts as a tumor suppressor in cutaneous melanoma by restraining PI3K/akt signaling.
Shen Q; Han Y; Wu K; He Y; Jiang X; Liu P; Xia C; Xiong Q; Liu R; Chen Q; Zhang Y; Zhao S; Yang C; Chen Y
Signal Transduct Target Ther; 2022 May; 7(1):147. PubMed ID: 35504869
[TBL] [Abstract] [Full Text] [Related]
3. Silencing FYVE, RhoGEF, and PH domain containing 1 (FGD1) suppresses melanoma progression by inhibiting PI3K/akt signaling pathway.
Niu Z; Li Y; Xu Y; Jiang W; Tao R; Chen Y; Han Y
Bioengineered; 2021 Dec; 12(2):12193-12205. PubMed ID: 34783295
[TBL] [Abstract] [Full Text] [Related]
4. Distinct Molecular Profiles and Immunotherapy Treatment outcomes of V600E and V600K
Pires da Silva I; Wang KYX; Wilmott JS; Holst J; Carlino MS; Park JJ; Quek C; Wongchenko M; Yan Y; Mann G; Johnson DB; McQuade JL; Rai R; Kefford RF; Rizos H; Scolyer RA; Yang JYH; Long GV; Menzies AM
Clin Cancer Res; 2019 Feb; 25(4):1272-1279. PubMed ID: 30630828
[TBL] [Abstract] [Full Text] [Related]
5. Loss of Phd2 cooperates with BRAF
Liu S; Zhang G; Guo J; Chen X; Lei J; Ze K; Dong L; Dai X; Gao Y; Song D; Ecker BL; Yang R; Feltcher C; Peng K; Feng C; Chen H; Lee RX; Kerestes H; Niu J; Kumar S; Xu W; Zhang J; Wei Z; Martin JS; Liu X; Mills G; Lu Y; Guo W; Sun L; Zhang L; Weeraratna A; Herlyn M; Wei W; Lee FS; Xu X
Nat Commun; 2018 Dec; 9(1):5426. PubMed ID: 30575721
[TBL] [Abstract] [Full Text] [Related]
6. Revisiting the clinical and Biologic Relevance of Partial PTEN Loss in Melanoma.
Giles KM; Rosenbaum BE; Berger M; Izsak A; Li Y; Illa Bochaca I; Vega-Saenz de Miera E; Wang J; Darvishian F; Zhong H; Osman I
J Invest Dermatol; 2019 Feb; 139(2):430-438. PubMed ID: 30148988
[TBL] [Abstract] [Full Text] [Related]
7. Continuous Petri Nets and microRNA Analysis in Melanoma.
Russo G; Pennisi M; Boscarino R; Pappalardo F
IEEE/ACM Trans Comput Biol Bioinform; 2018; 15(5):1492-1499. PubMed ID: 28767374
[TBL] [Abstract] [Full Text] [Related]
8. High cytotoxic T-lymphocyte-associated antigen 4 and phospho-akt expression in tumor samples predicts poor clinical outcomes in ipilimumab-treated melanoma patients.
Chakravarti N; Ivan D; Trinh VA; Glitza IC; Curry JL; Torres-Cabala C; Tetzlaff MT; Bassett RL; Prieto VG; Hwu WJ
Melanoma Res; 2017 Feb; 27(1):24-31. PubMed ID: 27768639
[TBL] [Abstract] [Full Text] [Related]
9. TrkA is amplified in malignant melanoma patients and induces an anti-proliferative response in cell lines.
Pasini L; Re A; Tebaldi T; Ricci G; Boi S; Adami V; Barbareschi M; Quattrone A
BMC Cancer; 2015 Oct; 15():777. PubMed ID: 26496938
[TBL] [Abstract] [Full Text] [Related]
10. Macrophage migration inhibitory factor engages PI3K/akt signalling and is a prognostic factor in metastatic melanoma.
Oliveira CS; de Bock CE; Molloy TJ; Sadeqzadeh E; Geng XY; Hersey P; Zhang XD; Thorne RF
BMC Cancer; 2014 Aug; 14():630. PubMed ID: 25168062
[TBL] [Abstract] [Full Text] [Related]
11. Is biomarker research advancing in the era of personalized medicine for head and neck cancer?
Yokota T
Int J Clin Oncol; 2014 Apr; 19(2):211-9. PubMed ID: 24442754
[TBL] [Abstract] [Full Text] [Related]
12. The biology and management of uveal melanoma.
Sato T; Han F; Yamamoto A
Curr Oncol Rep; 2008 Sep; 10(5):431-8. PubMed ID: 18706273
[TBL] [Abstract] [Full Text] [Related]
13. Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinib.
Agulnik M; da Cunha Santos G; Hedley D; Nicklee T; Dos Reis PP; Ho J; Pond GR; Chen H; Chen S; Shyr Y; Winquist E; Soulieres D; Chen EX; Squire JA; Marrano P; Kamel-Reid S; Dancey J; Siu LL; Tsao MS
J Clin Oncol; 2007 Jun; 25(16):2184-90. PubMed ID: 17538163
[TBL] [Abstract] [Full Text] [Related]
14. Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127.
Dragovich T; McCoy S; Fenoglio-Preiser CM; Wang J; Benedetti JK; Baker AF; Hackett CB; Urba SG; Zaner KS; Blanke CD; Abbruzzese JL
J Clin Oncol; 2006 Oct; 24(30):4922-7. PubMed ID: 17050876
[TBL] [Abstract] [Full Text] [Related]
15. Activation of c-jun N-terminal kinase is associated with cell proliferation and shorter relapse-free period in superficial spreading malignant melanoma.
Jørgensen K; Davidson B; Flørenes VA
Mod Pathol; 2006 Nov; 19(11):1446-55. PubMed ID: 16951673
[TBL] [Abstract] [Full Text] [Related]
16. Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma.
Rothenberg ML; LaFleur B; Levy DE; Washington MK; Morgan-Meadows SL; Ramanathan RK; Berlin JD; Benson AB; Coffey RJ
J Clin Oncol; 2005 Dec; 23(36):9265-74. PubMed ID: 16361624
[TBL] [Abstract] [Full Text] [Related]
17. Extramammary Paget's disease: analysis of growth signal pathway from the human epidermal growth factor receptor 2 protein.
Ogawa T; Nagashima Y; Wada H; Akimoto K; Chiba Y; Nagatani T; Inayama Y; Yao M; Aoki I; Ikezawa Z
Hum Pathol; 2005 Dec; 36(12):1273-80. PubMed ID: 16311120
[TBL] [Abstract] [Full Text] [Related]
18. Expression of activated akt and PTEN in malignant melanomas: relationship with clinical outcome.
Slipicevic A; Holm R; Nguyen MT; Bøhler PJ; Davidson B; Flørenes VA
Am J Clin Pathol; 2005 Oct; 124(4):528-36. PubMed ID: 16146807
[TBL] [Abstract] [Full Text] [Related]
